Unresectable Malignant Solid Neoplasm Clinical Trials

15 studies are recruiting for unresectable malignant solid neoplasm in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

   This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Comprehensive Cancer Center, Duarte, California

   Locations

   18 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05372614 on ClinicalTrials.gov

2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

   This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) …

   Stage

   Phase 2

   Ages

   Any age

   Site

   University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

   Locations

   482 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564377 on ClinicalTrials.gov

3. Adding Spatially Fractionated Radiation Therapy to Standard Palliative Radiation for Improving Disease-Related Symptoms in Patients With Unresectable Solid Tumors

   This clinical trial evaluates whether adding spatially fractionated radiation therapy (SFRT) to standard palliative external beam radiation therapy (EBRT) improves disease-related symptoms in patients with solid tumors that cannot be removed by surgery (unresectable). SFRT, originally termed GRID t…

   Stage

   Not phased

   Ages

   15 and older

   Site

   Mayo Clinic in Arizona, Scottsdale, Arizona

   Locations

   2 in total

   Run by

   Mayo Clinic

   See if you can join NCT07856394 on ClinicalTrials.gov

4. Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

   This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surger…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

   Locations

   22 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05803382 on ClinicalTrials.gov

5. MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers

   This phase I trial tests the safety, side effects, and best dose of MTI-301 in treating patients with solid cancers that have spread from where they first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and that have not responded …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic in Florida, Jacksonville, Florida

   Run by

   Mayo Clinic

   See if you can join NCT06911008 on ClinicalTrials.gov

6. Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

   This phase I trial identifies the side effects and best dose of DS-8201a and olaparib in treating patients with HER2-expressing cancers that have spread to other places in the body or cannot be removed by surgery or ovarian cancer that remains despite treatment with a platinum treatment (platinum r…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida

   Locations

   13 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04585958 on ClinicalTrials.gov

7. Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

   This phase I trial tests the safety, side effects, and best dose of azenosertib in combination with trastuzumab deruxtecan in treating patients with HER2-positive gastric or gastroesophageal junction cancer and other HER2-positive solid tumors that have spread to nearby tissue or lymph nodes (local…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT MD Anderson Cancer Center, Houston, Texas

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06364410 on ClinicalTrials.gov

8. Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

   This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tumors that have spread to other places in the body (advanced). Peposertib and tuvusertib stop the growth of tumor cells by blocking some of t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland

   Locations

   7 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05687136 on ClinicalTrials.gov

9. Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

   This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain prot…

   Stage

   Phase 1

   Ages

   16 and older

   Site

   Mayo Clinic in Florida, Jacksonville, Florida

   Run by

   Mayo Clinic

   See if you can join NCT05269381 on ClinicalTrials.gov

10. Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

    This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope Comprehensive Cancer Center, Duarte, California

    Locations

    36 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT05327010 on ClinicalTrials.gov

11. Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

    This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with binimetinib in treating patients with solid tumors that carry RAS alterations and that have spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectable). ZEN0…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UT MD Anderson Cancer Center, Houston, Texas

    Locations

    4 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT05111561 on ClinicalTrials.gov

12. Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

    This phase I trial tests the safety, side effects, and best dose of novobiocin in treating cancer patients with alterations in deoxyribonucleic acid (DNA) repair genes. Novobiocin is an antibiotic that blocks the activity of a protein called DNA polymerase theta, which helps repair DNA that has bec…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Comprehensive Cancer Center, Duarte, California

    Locations

    23 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT05687110 on ClinicalTrials.gov

13. Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

    This phase I trial tests the safety, side effects, and best dose of ZEN003694 when given together with abemaciclib in treating patients with NUT carcinoma, breast cancer or other solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or can…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Keck Medicine of USC Koreatown, Los Angeles, California

    Locations

    7 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT05372640 on ClinicalTrials.gov

14. TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

    This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), that cannot be removed by surgery (unresectable), that has spread from…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California Davis Comprehensive Cancer Center, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT07189195 on ClinicalTrials.gov

15. Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

    This phase I trial tests the safety, side effects, and best dose of pidnarulex in combination with trastuzumab deruxtecan in treating patients with breast cancer and other solid tumors that express varying levels of a protein called HER2 and that has spread from where it first started (primary site…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    2 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT07137416 on ClinicalTrials.gov